SoluFlex Link™ ADC Platform

Features of the
SoluFlex Link™ Hydrophilic Linkers

새로운 linker 구조를 통해 DAR 8 환경에서도 비접합(Unconjugated) 항체 수준에 가까운 친수성을 구현합니다.
고친수성(High-hydrophilic) Branched Linker 구조를 적용해 소수성(Hydrophobic) 페이로드의 노출을 최소화합니다.

HIC-HPLC Chromatogram Data³

HIC-HPLC Chromatogram Data

Branched Solubilizing Linker

Compatible with all cleavable and non-cleavable linkers and payloads (Branched linker flexibility)
Improved hydrophilicity (Superior to PEG in hydrophilic properties)
Optimized pharmacokinetic (PK) profile
Low immunogenicity potential
High conjugation and purification yields
Thermal stability, freeze/thaw stability
Target dependent in vitro efficacy
No toxic metabolites

1.DAR : Drug-to-antibody ratio
2.Poly Ethylene Glycol
3.Using Exatecan-Topo 1 inhibitor drug

롯데바이오로직스는 ADC 플랫폼을 기반으로 다양한 Linker-Payload 조합을 제공하는 ADC Toolbox 서비스를 운영합니다. 최적화된 Toolbox를 통해 유망 후보 조합을 효율적으로 선별하여 ADC 개발의 성공 가능성을 높이고, 임상 진입까지의 시간을 단축할 수 있도록 지원합니다.

Antibody

Conjugating unit

Site-specific conjugation
Other (Applicable to all conjugating units)

SoluFlex Link™-Linker

SoluFlex Link™
With Cleavable linkers
1. Val-Cit
2. Val-Ala
3. Phe-Gly
4. β-Glucuronide
With Non-cleavable linkers
1. MC
2. MP
Other (Applicable to all linkers)

Payload (Novel & Derivatives)

SoluFlex Link™ Linker with
Nemorubicin analog (Novel)*
Nemorubicin : DNA damaging agent
Exatecan : Topoisomerase I inhibitor
Ispinesib : Kinesin inhibitor (KSP)
Attenuated PBD dimer : DNA Alkylating agent
Duocarmycin DM analog : DNA Alkylating agent
Seco DUBA analog : DNA Alkylating agent
MMAE : Microtubule inhibitor
MMAF : Microtubule inhibitor
Other (Applicable to all payloads)

* Demonstrated low conversion to toxic metabolites